#Japan #Tokyo #HIV Awareness #Gilead Sciences #HIV/AIDS GAP6

Gilead's Commitment to Ending the HIV Epidemic: Launching the HIV/AIDS GAP6 Special Website

On October 1, 2025, Gilead Sciences Inc. unveiled a special website for the HIV/AIDS GAP6 consortium, a partnership aimed at ending the HIV epidemic in Japan. This initiative represents a significant collaborative effort between Gilead and various organizations that support people living with HIV, reinforcing their commitment to raising awareness and combating stigma associated with HIV.

The Goals of the HIV/AIDS GAP6 Consortium

Founded on World AIDS Day in 2021, the HIV/AIDS GAP6 aims to address six major gaps in understanding related to HIV/AIDS. Over its five-year journey, GAP6 has made substantial strides towards improving testing, prevention, and treatment of HIV while promoting an inclusive community for individuals affected by the virus.

The newly launched website, accessible at https://www.endinghiv-gap6.jp, serves as a platform to share updates from the seven participating organizations including Place Tokyo, akta, ZEL, Habataki Welfare Project, Miraculous Club, Kanazawa Rainbow Pride, and Gilead Sciences. Here, the public can explore the initiatives undertaken by these groups and follow the trajectory of their collective efforts.

Campaigns and Initiatives

GAP6 has previously filed three requests for action to the government targeting the objective of ending the HIV epidemic. These requests have been publicly disclosed, encouraging society at large to engage with and understand the HIV epidemic, ultimately fostering actions that promote health and awareness.

Furthermore, Gilead is committed to supporting the United Nations Joint Programme on HIV/AIDS (UNAIDS) goal of ending the HIV epidemic by 2030. This involves enhancing access to HIV testing, improving accessibility to PrEP (pre-exposure prophylaxis), creating better treatment environments, and advocating for a society free of stigma surrounding HIV.

Understanding HIV and AIDS

HIV, or Human Immunodeficiency Virus, attacks the immune system by infecting and destroying CD4 T cells, which are crucial for fighter infection and disease. When HIV progresses, it can lead to AIDS (Acquired Immunodeficiency Syndrome), a group of symptoms representing the most severe stages of HIV infection. In Japan, individuals are diagnosed with AIDS once they exhibit one of 23 designated conditions.

Gilead Sciences aims to bring breakthroughs in medicine for life-threatening conditions including HIV, hepatitis, COVID-19, and cancer. With over 35 years of expertise and advancement in biopharmaceuticals, Gilead is dedicated to innovating healthcare solutions for a healthier world.

For more detailed insights regarding the HIV/AIDS GAP6 consortium and Gilead's initiatives, visit the special website and join us in the fight against HIV. Together, we can work towards a future where HIV is no longer a public health threat.